ARS Pharmaceuticals

Timeline

1. Mar 26, 2026 FDA FDA New indication / efficacy supplement: NEFFY (epinephrine) — NDA214697/2, Mar 26, 2026. Applicant at approval: ARS Pharmaceuticals Operations, Inc. source ↗
2. Sep 29, 2025 Debt Debt financing: $250M (up to, as announced), announced Sep 29, 2025. Source: company release on GlobeNewswire. source ↗
3. Mar 5, 2025 FDA FDA New indication / efficacy supplement: NEFFY (epinephrine) — NDA214697/1, Mar 5, 2025. Applicant at approval: ARS Pharmaceuticals Operations, Inc. source ↗

Funding

Debt: $250.0M. Last 2 years.

• Sep 29, 2025 Debt financing: $250M (up to, as announced), announced Sep 29, 2025. Source: company release on GlobeNewswire. source ↗

FDA records (last 2 years)

• Mar 26, 2026 FDA New indication / efficacy supplement: NEFFY (epinephrine) — NDA214697/2, Mar 26, 2026. Applicant at approval: ARS Pharmaceuticals Operations, Inc. source ↗
• Mar 5, 2025 FDA New indication / efficacy supplement: NEFFY (epinephrine) — NDA214697/1, Mar 5, 2025. Applicant at approval: ARS Pharmaceuticals Operations, Inc. source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

• InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗